Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme.
about
Industry sponsorship and research outcomeBias in published cost effectiveness studies: systematic review.Pharmaceutical industry sponsorship and research outcome and quality: systematic reviewAssessing the impact of the Australia-United States Free Trade Agreement on Australian and global medicines policyOne step forward, one step sideways? Expanding research capacity for neglected diseasesToward a treaty on safety and cost-effectiveness of pharmaceuticals and medical devices: enhancing an endangered global public goodA qualitative study of manufacturers' submissions to the UK NICE single technology appraisal process.HEE-GER: a systematic review of German economic evaluations of health care published 1990-2004Interpreting the results of secondary end points and subgroup analyses in clinical trials: should we lock the crazy aunt in the attic?Health systems and sustainability: doctors and consumers differ on threats and solutions.Cost-effectiveness analysis for cliniciansDose-sparing and safety-enhancing effects of an IGF-I-based dosing regimen in short children treated with growth hormone in a 2-year randomized controlled trial: therapeutic and pharmacoeconomic considerations.How to change clinical behaviour: no answers yet.Efforts to ban direct-to-consumer advertising in New Zealand: a call to action.Confidentiality: consent is not sufficient.Drug policy down under: Australia's pharmaceutical benefits scheme.What affects the quality of economic analysis for life-saving investments?A glimpse into the black box of cost-effectiveness analysesWhen are statins cost-effective in cardiovascular prevention? A systematic review of sponsorship bias and conclusions in economic evaluations of statins.Use of pharmacoeconomics in prescribing research. Part 1: costs--moving beyond the acquisition price for drugs.The funding and use of high-cost medicines in Australia: the example of anti-rheumatic biological medicinesSUPPORT Tools for evidence-informed health Policymaking (STP) 12: Finding and using research evidence about resource use and costs.Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdleSelecting the Acceptance Criteria of Medicines in the Reimbursement List of Public Health Insurance of Iran, Using the "Borda" Method: a Pilot StudyPalivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease.The pharmacoeconomics of acne treatment: where are we heading?Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV)Cost-effectiveness thresholds: pros and cons.The history of health technology assessment in Australia.The state of health economic and pharmacoeconomic evaluation research in Zimbabwe: A review.6-STEPPPs: A Modular Tool to Facilitate Clinician Participation in Fair Decisions for Funding New Cancer DrugsThe evaluation and use of economic evidence to inform cancer drug reimbursement decisions in Canada.Systematic review and quality assessment of cost-effectiveness analysis of pharmaceutical therapies for advanced colorectal cancer.Anti-angiogenic agent ramucirumab: meaningful or marginal?Risk of bias in trial-based economic evaluations: identification of sources and bias-reducing strategies.Systematic review of the quality of economic evaluations in the otolaryngology literature.Exploring Uncertainty in Economic Evaluations of Drugs and Medical Devices: Lessons from the First Review of Manufacturers' Submissions to the French National Authority for Health.Economic Evaluations of Pharmaceuticals Granted a Marketing Authorisation Without the Results of Randomised Trials: A Systematic Review and Taxonomy.Health technology assessment in Poland and Scotland: comparison of process and decisions.Pitfalls associated with commonly used methods for pharmacoeconomic analyses.
P2860
Q24234843-59D7ED63-EC9E-4C57-BFA1-71AF31BC2CAEQ24541365-24A543A6-F082-493C-ACD2-A21279788736Q24673248-4D678F9D-086F-42E9-A601-E792834D8FBFQ24812956-F05A6E5A-B5B9-47A0-8521-21D3992DCAA5Q28749681-4C2FE87F-9B0E-4FCD-8D9D-6D930D728D7BQ28768386-4BA49D77-0E37-4D31-A5DF-2168DE5EC6C7Q30505263-67FC8CDF-0F3B-441C-A384-8DC7916454F3Q33269184-B6CF5911-D68F-4B97-87DE-4A92721ACD04Q33805130-CB48B994-0A35-4CD9-9320-E7DC81A2DAEFQ33893891-C659A972-F53B-473B-806E-9D5FAE5B0239Q34148072-76FC8D27-9402-4B7E-B2FA-134164D93E9CQ34159910-3E1D648A-3017-47E2-86D5-68D840F5F30AQ34223408-4269DD95-9F98-4455-B65E-8B2D9568C98CQ34223415-996C0BEF-8617-4687-B8E4-DA2A1A6F8766Q34223423-52555F58-2AD0-4EDB-AA1E-7A175E84D65BQ34328049-ABAE0677-91DA-41F1-8E56-AA4706B2EE74Q34546567-FEE5EBCE-5698-48EE-B766-1A77893CD098Q34765208-9F46B8CF-B9FA-4CD8-9071-DF7012696DE8Q34828582-3AEDC748-5F50-48F6-BA32-31B2691984E4Q35073412-B403D8B3-6326-4FB5-A6D7-CDFA403FCB6BQ35688491-1E824B55-98B5-4B73-A19A-7713FD6C2821Q35734439-8ADEC973-84F3-406F-AB3B-9C18EDD4B825Q35925125-F0F7713F-568E-48F1-9072-55C52BA3CA19Q36358445-7E2FD7B3-B797-43B7-B3C6-E9C90769891EQ36922280-CCBE5FF9-E319-47F0-8B91-1F0896AFE10BQ37084277-18B7B3DD-4940-44E4-9989-2FF886063D86Q37290618-D665EECF-9BE8-479C-A607-B8FED66393B9Q37498173-523DB615-C408-4359-9D03-398DED4A111BQ37509238-3B6E5BC6-687B-4107-8880-521475CFED39Q37672821-3BFBA3E8-B187-4494-8BCF-FFC1083C0BC9Q37790982-B48B96A3-597C-4AC3-9F44-DCCDD1105485Q38074371-E267B2EB-E300-4ACE-BC6B-C2B87490E6EBQ38095230-40391278-DAAF-461F-8A14-8B22CD5848D2Q38194159-AD5E8F6E-D503-4AC7-B4AE-E5654B17068BQ38241647-7670F222-A4A5-49A9-BA47-16A9C7387A0BQ38266844-D77A1B5E-5082-4AD3-BC80-63DC8191258BQ38717853-4BD49C64-67FC-4E76-B4D3-7796E5E77051Q38990039-DC693014-82DE-40F4-8D15-06599F2DBAAFQ39614547-DE61CA74-3E2B-4801-BDCE-41CF2D823ADAQ40661362-84CC5944-122E-4CDC-88BC-F1EE78755832
P2860
Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme.
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Problems with the interpretati ...... harmaceutical Benefits Scheme.
@ast
Problems with the interpretati ...... harmaceutical Benefits Scheme.
@en
type
label
Problems with the interpretati ...... harmaceutical Benefits Scheme.
@ast
Problems with the interpretati ...... harmaceutical Benefits Scheme.
@en
prefLabel
Problems with the interpretati ...... harmaceutical Benefits Scheme.
@ast
Problems with the interpretati ...... harmaceutical Benefits Scheme.
@en
P2093
P356
P1476
Problems with the interpretati ...... harmaceutical Benefits Scheme.
@en
P2093
P304
P356
10.1001/JAMA.283.16.2116
P407
P577
2000-04-01T00:00:00Z